reddit.com· r/GLP1ResearchTalk · Reddit·· 7 days agoPickScore70
The Next Generation of Weight-Loss Drugs Is Almost Here
In brief
A Reddit thread on r/GLP1ResearchTalk debates next-generation amylin-based weight-loss drugs presented at EASD 2026, where CagriSema (cagrilintide plus semaglutide) showed 22.4% weight loss over 52 weeks versus placebo (p<0.0001) and Lilly reported Phase IIb data for its amylin analogue eloralintide. Commenters split over whether high dropout rates in higher-dose eloralintide plus tirzepatide combinations signal tolerability problems, with others blaming faster titration; Lilly has not disclosed dropout reasons. Novo Nordisk submitted CagriSema's NDA to the FDA in December 2025, with a decision expected in Q4 2026.
Why it matters
EASD 2026 amylin data and community pushback on dropout rates add context to coming obesity-drug approvals.
Source: reddit.com